Login to Your Account



BMS Offers Lifeline to Summit's Seglin Tech in $300M Alliance

By Cormac Sheridan
Staff Writer

Wednesday, September 12, 2012
Shares in Summit plc gained 26 percent Tuesday on news of a collaboration agreement on the company's Seglin technology with Bristol-Myers Squibb Co. (BMS) that could be worth as much as $300 million in research, development and regulatory milestones.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription